By Fineline Cube 
China-based Luye Pharma Group (HKG: 2186) announced the market launch of Rotigotine Luye in the UK. This generic version of UCB’s (EBR: UCB) Neupro (rotigotine) is approved for treating early- and late-stage idiopathic Parkinson’s disease and moderate to severe idiopathic restless leg syndrome. The launch marks a significant milestone in Luye Pharma’s global expansion strategy.
Product Advantages
Rotigotine Luye demonstrates bioequivalence with Neupro, offering patients a cost-effective alternative. The product features a lower drug loading capacity and a patch size 8% smaller than Neupro, enhancing patient comfort and convenience. Notably, the adhesive matrix layer of Rotigotine Luye excludes sodium metabisulfite, a known contact allergen, reducing the risk of allergic reactions and improving safety profiles.
Market Impact
As the first generic version of Neupro to be listed in the UK, Rotigotine Luye is poised to capture a significant share of the market. This approval underscores Luye Pharma’s commitment to providing accessible and effective treatments for neurological disorders, further solidifying its position in the global pharmaceutical industry.-Fineline Info & Tech